文献速递肺结节与肺癌

术前诊断性活检对I期非小细胞肺癌气道播散及结局的影响

Impact of Preoperative Diagnostic Biopsy Procedure on Spread Through Airspaces and Related Outcomes in Resected Stage I Non-Small Cell Lung Cancer.
PubMed 文献 · Chest · 2022-05-10

该回顾性队列研究纳入2,169例病理I期NSCLC手术患者,STAS阳性率29.4%。术前经皮穿刺或支气管镜活检与STAS风险无显著关联,校正活检后STAS仍是复发的显著危险因素(HR 1.72),STAS阳性患者亚肺叶切除与复发和肺癌特异性死亡显著相关,术前活检不影响STAS相关预后。

要点

  • 术前活检(经皮或支气管镜)不增加I期NSCLC的STAS风险。
  • STAS阳性是复发的独立危险因素(HR 1.72,95%CI 1.20-2.48)。
  • STAS阳性者亚肺叶切除与复发和肺癌特异性死亡显著相关。

核心结论

  • I期NSCLC术前活检与STAS风险升高无关,也不影响STAS相关预后。

研究设计与样本

  • 回顾性队列研究,纳入2011年1月至2019年12月韩国首尔大学盆唐医院2,169例病理I期NSCLC手术患者。

主要发现

  • 2,169例中638例(29.4%)STAS阳性。
  • 术前活检(经皮穿刺和支气管镜活检)与STAS无显著关联。
  • 校正术前活检后,STAS是癌症复发的显著危险因素(HR 1.72;95%CI 1.20-2.48)。
  • STAS阳性患者中,亚肺叶切除是复发的显著危险因素(HR 3.20;95%CI 1.65-6.21)。
  • STAS阳性患者中,亚肺叶切除是肺癌特异性死亡的显著危险因素(HR 12.71;95%CI 3.68-43.92)。

关键数值与推荐

  • STAS阳性率29.4%(638/2,169)。
  • STAS与复发:HR 1.72(95%CI 1.20-2.48)。
  • STAS阳性者亚肺叶切除与复发:HR 3.20(95%CI 1.65-6.21)。
  • STAS阳性者亚肺叶切除与肺癌特异性死亡:HR 12.71(95%CI 3.68-43.92)。

临床怎么用

  • I期NSCLC术前活检无需过度顾虑STAS风险。
  • STAS阳性患者应警惕复发风险,尤其行亚肺叶切除时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumor spread through airspaces (STAS) is a recently determined pathologic phenomenon of lung cancer with significant prognostic impact. This study aimed to analyze the unexplored correlation between preoperative biopsy procedure and a higher risk of STAS and its impact on STAS-related outcomes in resected stage I non-small cell lung cancer (NSCLC). RESEARCH QUESTION: Does preoperative biopsy procedure affect the risk of STAS and STAS-related outcomes in surgically treated stage I NSCLC? STUDY DESIGN AND METHODS: We examined 2,169 patients who underwent surgery for pathologic stage I NSCLC from January 2011 through December 2019 at the Seoul National University Bundang Hospital, a tertiary center in South Korea. Factors including percutaneous needle biopsy (PCNB) and bronchoscopic biopsy were assessed for determining the association between preoperative biopsy procedure and an elevated risk of STAS. In addition, the impact of preoperative biopsy on STAS-related prognosis (recurrence and lung cancer-specific mortality) was evaluated with multivariate Cox regression analyses. RESULTS: STAS findings were positive in 638 of 2,169 patients (29.4%). An insignificant association was found between preoperative biopsy (both PCNB and bronchoscopic biopsy) and STAS. After adjustments for preoperative tumor biopsy, STAS was a significant risk factor for cancer recurrence (hazard ratio [HR], 1.72; 95% CI, 1.20-2.48). Additionally, sublobar resection remained a significant risk factor for recurrence (HR, 3.20; 95% CI, 1.65-6.21) and lung cancer-specific mortality (HR, 12.71; 95% CI, 3.68-43.92) in patients with positive STAS findings. However, this association was insignificant for patients without STAS. Preoperative biopsy was not a significant risk factor for either recurrence and mortality, regardless of STAS positivity. INTERPRETATION: Preoperative biopsy in stage I NSCLC neither was associated with an elevated risk of STAS nor influenced the prognosis related to STAS. Physicians can be less apprehensive about performing preoperative biopsy in relationship to STAS.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Lee GY, Chung JH, Cho S, et al. Impact of Preoperative Diagnostic Biopsy Procedure on Spread Through Airspaces and Related Outcomes in Resected Stage I Non-Small Cell Lung Cancer. Chest. 2022. PMID: 35562060. doi:10.1016/j.chest.2022.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。